Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

March 9, 2006 at 9:36 AM

Cell Therapeutics pares annual loss to $102 million

Cell Therapeutics shares were up 3 percent in midday trading after the company reported its fourth-quarter and full-year results.

The Seattle biotechnology company lost $18.7 million in the fourth quarter, or 27 cents a share, down from $43.5 million in the same period last year. For the year, the company recorded a loss of $102.5 million, $1.59 a share, down from $252.3 million, $4.67 a share, in 2004.

Cell Therapeutics booked a $71.2 million gain from the sale of Trisenox in 2005, including $40.7 million in the fourth quarter. The company sold the leukemia drug, its only approved product, to Cephalon last summer.

The company had $69.1 million in cash and equivalents on Dec. 31 and spent $73.8 million on operations in 2005, including a $12.8 million restructuring charge.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►